BACKGROUND: The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV)-infected children and adolescents on combination antiretroviral therapy (cART) has not been compared globally. METHODS: We analyzed cohort data from the International Epidemiologic Databases to Evaluate AIDS and the Collaboration of Observational HIV Epidemiological Research in Europe. We included HIV-infected children aged <16 years at cART initiation from 1996 onward. We used Cox models to calculate hazard ratios (HRs), adjusted for region and origin, sex, cART start year, age, and HIV/AIDS stage at cART initiation. RESULTS: We included 24 991 children from eastern Africa, southern Africa, Europe and Asia; 26 developed KS after starting cART. Incidence rates per 100 000 person-years (PYs) were 86 in eastern Africa (95% confidence interval [CI], 55-133), 11 in southern Africa (95% CI, 4-35), and 81 (95% CI, 26-252) in children of sub-Saharan African (SSA) origin in Europe. The KS incidence rates were 0/100 000 PYs in children of non-SSA origin in Europe (95% CI, 0-50) and in Asia (95% CI, 0-27). KS risk was lower in girls than in boys (adjusted HR [aHR], 0.3; 95% CI, .1-.9) and increased with age (10-15 vs 0-4 years; aHR, 3.4; 95% CI, 1.2-10.1) and advanced HIV/AIDS stage (CDC stage C vs A/B; aHR, 2.4; 95% CI, .8-7.3) at cART initiation. CONCLUSIONS: HIV-infected children from SSA but not those from other regions, have a high risk of developing KS after cART initiation. Early cART initiation in these children might reduce KS risk.
BACKGROUND: The burden of Kaposi sarcoma (KS) in human immunodeficiency virus (HIV)-infectedchildren and adolescents on combination antiretroviral therapy (cART) has not been compared globally. METHODS: We analyzed cohort data from the International Epidemiologic Databases to Evaluate AIDS and the Collaboration of Observational HIV Epidemiological Research in Europe. We included HIV-infectedchildren aged <16 years at cART initiation from 1996 onward. We used Cox models to calculate hazard ratios (HRs), adjusted for region and origin, sex, cART start year, age, and HIV/AIDS stage at cART initiation. RESULTS: We included 24 991 children from eastern Africa, southern Africa, Europe and Asia; 26 developed KS after starting cART. Incidence rates per 100 000 person-years (PYs) were 86 in eastern Africa (95% confidence interval [CI], 55-133), 11 in southern Africa (95% CI, 4-35), and 81 (95% CI, 26-252) in children of sub-Saharan African (SSA) origin in Europe. The KS incidence rates were 0/100 000 PYs in children of non-SSA origin in Europe (95% CI, 0-50) and in Asia (95% CI, 0-27). KS risk was lower in girls than in boys (adjusted HR [aHR], 0.3; 95% CI, .1-.9) and increased with age (10-15 vs 0-4 years; aHR, 3.4; 95% CI, 1.2-10.1) and advanced HIV/AIDS stage (CDC stage C vs A/B; aHR, 2.4; 95% CI, .8-7.3) at cART initiation. CONCLUSIONS:HIV-infectedchildren from SSA but not those from other regions, have a high risk of developing KS after cART initiation. Early cART initiation in these children might reduce KS risk.
Authors: Dimitra Bourboulia; Diana Aldam; Dimitrios Lagos; Elizabeth Allen; Ian Williams; David Cornforth; Andrew Copas; Chris Boshoff Journal: AIDS Date: 2004-02-20 Impact factor: 4.177
Authors: Soren Gantt; Abel Kakuru; Anna Wald; Victoria Walusansa; Lawrence Corey; Corey Casper; Jackson Orem Journal: Pediatr Blood Cancer Date: 2010-05 Impact factor: 3.167
Authors: Cornelia Feiterna-Sperling; Christoph Königs; Gundula Notheis; Bernd Buchholz; Renate Krüger; Katharina Weizsäcker; Josef Eberle; Nikola Hanhoff; Barbara Gärtner; Harald Heider; Detlev H Krüger; Jörg Hofmann Journal: Med Microbiol Immunol Date: 2016-05-30 Impact factor: 3.402
Authors: Edgar P Simard; Meredith S Shiels; Kishor Bhatia; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-11-08 Impact factor: 4.254
Authors: Veenu Minhas; Brad P Brayfield; Kay L Crabtree; Chipepo Kankasa; Charles D Mitchell; Charles Wood Journal: BMC Infect Dis Date: 2010-05-12 Impact factor: 3.090
Authors: Lisa M Butler; Grant Dorsey; Wolfgang Hladik; Philip J Rosenthal; Christian Brander; Torsten B Neilands; Georgina Mbisa; Denise Whitby; Photini Kiepiela; Anisa Mosam; Similo Mzolo; Sheila C Dollard; Jeffrey N Martin Journal: J Infect Dis Date: 2009-08-01 Impact factor: 5.226
Authors: Frédérique Chammartin; Cam Ha Dao Ostinelli; Kathryn Anastos; Antoine Jaquet; Ellen Brazier; Steven Brown; Francois Dabis; Mary-Ann Davies; Stephany N Duda; Karen Malateste; Denis Nash; Kara Wools-Kaloustian; Per M von Groote; Matthias Egger Journal: BMJ Open Date: 2020-05-15 Impact factor: 2.692
Authors: Heather Haq; Peter Elyanu; Shaun Bulsara; Jason M Bacha; Liane R Campbell; Nader K El-Mallawany; Elizabeth M Keating; Grace P Kisitu; Parth S Mehta; Chris A Rees; Jeremy S Slone; Adeodata R Kekitiinwa; Mogomotsi Matshaba; Michael B Mizwa; Lumumba Mwita; Gordon E Schutze; Sebastian R Wanless; Michael E Scheurer; Joseph Lubega Journal: Cancers (Basel) Date: 2021-03-18 Impact factor: 6.639